An FDA announcement that semaglutide injection products, the GLP-1 medication in the blockbuster drugs Wegovy and Ozempic, are no longer in shortage
Back in 2005, a company called AstraZeneca came up with a new idea
With oral BPC-157 arginate salt at 500mcg per day, most users and animal studies report experiencing initial benefitsparticularly for gut health, soft tissue injury, or inflammation supportwithin the first 714 days of consistent daily use
Unlike oral medications, injectable semaglutide delivers a smaller total drug load to any single body area, making site reactions generally mild and self-limiting
These deadlines were established to allow for a transition period and to minimize disruption to patient care
However, its important to understand that retatrutide is not yet FDA approved